glp-1 egfr cut off receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Repurposing Diabetes Therapies in CKD:

Weight-loss plateau on Ozempic: What it means and how to fix it

As for addressing key questions remaining in regards to this topic we first suggest future studies to more thoroughly report maternal and treatment characteristics including trimester of exposure

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study

Less muscle means a somewhat lower resting metabolic rate, lower daily energy expenditure, and a smaller margin for error with your diet

Swissmedic [Internet]

JAMA Netw Open 7(1):e2350408e2350408 [DOI] [PMC free article] [PubMed] [Google Scholar] Deacon CF (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes